RhumbLine Advisers’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.62M Sell
316,935
-47,086
-13% -$454K ﹤0.01% 1510
2026
Q1
$2.7M Buy
364,021
+6,765
+2% +$71.2K ﹤0.01% 1706
2025
Q4
$4.2M Sell
357,256
-25,399
-7% -$274K ﹤0.01% 1485
2025
Q3
$2.95M Sell
382,655
-5,750
-1% -$40.3K ﹤0.01% 1698
2025
Q2
$2.84M Buy
388,405
+21,816
+6% +$176K ﹤0.01% 1691
2025
Q1
$3.48M Sell
366,589
-22,414
-6% -$280K ﹤0.01% 1538
2024
Q4
$6.41M Buy
389,003
+9,098
+2% +$141K 0.01% 1296
2024
Q3
$5.6M Sell
379,905
-2,431
-0.6% -$38K 0.01% 1368
2024
Q2
$5.3M Sell
382,336
-3,297
-0.9% -$46.7K 0.01% 1365
2024
Q1
$6.06M Buy
385,633
+694
+0.2% +$10.7K 0.01% 1314
2023
Q4
$6.23M Sell
384,939
-25,446
-6% -$416K 0.01% 1281
2023
Q3
$5.05M Buy
410,385
+749
+0.2% +$11.1K 0.01% 1337
2023
Q2
$6.58M Sell
409,636
-8,722
-2% -$144K 0.01% 1221
2023
Q1
$7.28M Buy
418,358
+12,582
+3% +$179K 0.01% 1125
2022
Q4
$3.75M Buy
405,776
+29,628
+8% +$276K 0.01% 1445
2022
Q3
$3.24M Buy
376,148
+16,812
+5% +$167K ﹤0.01% 1492
2022
Q2
$2.93M Buy
359,336
+57,275
+19% +$547K ﹤0.01% 1553
2022
Q1
$3.67M Buy
302,061
+19,588
+7% +$412K ﹤0.01% 1502
2021
Q4
$9.64M Buy
282,473
+9,103
+3% +$356K 0.01% 1004
2021
Q3
$13.2M Sell
273,370
-39,696
-13% -$1.84M 0.02% 806
2021
Q2
$14.1M Sell
313,066
-1,056
-0.3% -$46.8K 0.02% 801
2021
Q1
$15.2M Buy
314,122
+13,179
+4% +$686K 0.02% 739
2020
Q4
$16.2M Buy
300,943
+9,630
+3% +$435K 0.02% 643
2020
Q3
$10.7M Sell
291,313
-33,177
-10% -$1.23M 0.02% 735
2020
Q2
$10.1M Buy
324,490
+3,474
+1% +$96.3K 0.02% 769
2020
Q1
$8.86M Buy
321,016
+5,003
+2% +$150K 0.02% 712
2019
Q4
$9.24M Buy
316,013
+19,861
+7% +$473K 0.02% 878
2019
Q3
$5.66M Buy
296,152
+15,438
+5% +$362K 0.01% 1115
2019
Q2
$6.16M Buy
280,714
+31,116
+12% +$683K 0.01% 1083
2019
Q1
$5.11M Buy
249,598
+163,698
+191% +$2.84M 0.01% 1165
2018
Q4
$1.08M Buy
85,900
+31,639
+58% +$472K ﹤0.01% 1962
2018
Q3
$833K Sell
54,261
-928
-2% -$12.8K ﹤0.01% 2080
2018
Q2
$724K Buy
55,189
+3,144
+6% +$34.6K ﹤0.01% 2148
2018
Q1
$425K Sell
52,045
-930
-2% -$7.53K ﹤0.01% 2278
2017
Q4
$469K Sell
52,975
-9,400
-15% -$86.7K ﹤0.01% 2255
2017
Q3
$694K Buy
62,375
+875
+1% +$8.52K ﹤0.01% 2160
2017
Q2
$551K Buy
61,500
+2,135
+4% +$16.9K ﹤0.01% 2242
2017
Q1
$468K Buy
59,365
+1,674
+3% +$13.6K ﹤0.01% 2280
2016
Q4
$494K Buy
57,691
+4,657
+9% +$39.9K ﹤0.01% 2231
2016
Q3
$436K Buy
53,034
+1,499
+3% +$12.6K ﹤0.01% 2281
2016
Q2
$414K Buy
51,535
+1,740
+3% +$13.9K ﹤0.01% 2328
2016
Q1
$336K Buy
49,795
+465
+0.9% +$3.06K ﹤0.01% 2470
2015
Q4
$388K Buy
49,330
+4,975
+11% +$36.4K ﹤0.01% 2409
2015
Q3
$254K Buy
44,355
+1,765
+4% +$10.9K ﹤0.01% 2650
2015
Q2
$230K Buy
+42,590
New +$220K ﹤0.01% 2808
2014
Q2
Sell
-26,877
Closed -$93K 3048
2014
Q1
$93K Sell
26,877
-1,600
-6% -$6K ﹤0.01% 2930
2013
Q4
$103K Hold
28,477
﹤0.01% 2953
2013
Q3
$85K Sell
28,477
-323
-1% -$910 ﹤0.01% 2946
2013
Q2
$115K Buy
+28,800
New +$110K ﹤0.01% 3212

Other funds holding NEO

RhumbLine Advisers's NEO Position: Q2 2026 in Review

RhumbLine Advisers reduced its NeoGenomics (NEO) stake by 13% in Q2 2026, selling an estimated $454K and leaving 316,935 shares worth $4.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

RhumbLine Advisers first reported a position in NEO in Q2 2013 and has held it in 49 quarters since. The position peaked at $16.2M in Q4 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • RhumbLine Advisers held 316,935 shares of NeoGenomics worth $4.62M as of Q2 2026.
  • RhumbLine Advisers sold 47,086 NeoGenomics shares in Q2 2026, an estimated $454K.
  • NeoGenomics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1510 holding.
  • RhumbLine Advisers first reported a position in NeoGenomics in Q2 2013 and has held it in 49 quarters since.
  • RhumbLine Advisers's NeoGenomics position peaked at $16.2M in Q4 2020.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.